Sagimet (SGMT) Stock Soars 30% on Acne Drug Trial Plans

Sagimet Biosciences Stock Surges on Phase 3 Trial Announcement

Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT) surged by 30% after the company announced its plan to initiate a U.S.-based Phase 3 clinical trial for denifanstat, its treatment for moderate to severe acne. The trial is scheduled to begin in the second half of 2026, pending Investigational New Drug (IND) clearance.

Trial Background and Drug Potential

The decision to advance denifanstat in the U.S. follows positive Phase 3 results from a trial in China conducted by its partner, Ascletis Bioscience. Denifanstat is a once-daily oral medication that targets fatty acid synthase (FASN) inhibition to reduce sebum production. If approved, it would be the first innovative oral treatment for acne in over four decades, addressing a condition affecting about 10 million people in the U.S. annually.

Financial Strategy and Corporate Developments

Alongside the trial news, Sagimet announced it is prioritizing its dermatology franchise in its capital allocation strategy. The company also priced an underwritten offering of 29,166,700 shares of its Series A common stock at $6.00 per share, expecting to raise gross proceeds of approximately $175.0 million before expenses.

Market Outlook

The significant stock price increase reflects strong investor confidence in denifanstat's potential and the company's strategic focus. The upcoming milestones, including the IND application in mid-2026 and the trial initiation, will be critical factors for the company's valuation moving forward.

**FAQ**

**Q:** Why did Sagimet Biosciences' stock price increase sharply?
**A:** The stock rose 30% following the announcement of its plans to start a Phase 3 clinical trial in the U.S. for its oral acne drug, denifanstat.

**Q:** What makes denifanstat significant?
**A:** If approved, denifanstat would be the first new oral medication for acne in more than 40 years, offering a novel treatment mechanism by inhibiting sebum production.

**Q:** How is Sagimet funding its operations?
**A:** The company announced a stock offering expected to raise approximately $175 million to support its programs, including the prioritization of its dermatology franchise.

Source: Investing.com